Milestone Pharmaceuticals
MIST
40 hedge funds and large institutions have $29.7M invested in Milestone Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 7 closing their positions.
157% more call options, than puts
Call options by funds: $411K | Put options by funds: $160K
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 39 → 40 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.45% less ownership
Funds ownership: 58.63% → 53.18% (-5.5%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
51% less capital invested
Capital invested by funds: $60.7M → $29.7M (-$30.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$3.26M |
| 2 |
AFA
Alta Fundamental Advisers
New York
|
+$1.34M |
| 3 |
BlackRock
New York
|
+$1.33M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$461K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$3.48M |
| 2 |
Goldman Sachs
New York
|
-$3.27M |
| 3 |
Barclays
London,
United Kingdom
|
-$1.06M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$1.04M |
| 5 |
JP Morgan Chase
New York
|
-$634K |
MIST Hedge Fund Activity: Q4 2023 in Review
40 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2023, worth a combined $29.7M — down 51% from $60.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MIST positions and 7 closed out — a net gain of 1 holder — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Lion Point Capital, adding an estimated $3.26M. The largest seller was VR Adviser, cutting an estimated $3.48M.
- 40 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2023, up from 39 in Q3 2023.
- Funds reported $29.7M of Milestone Pharmaceuticals stock for Q4 2023, down 51% quarter-over-quarter.
- 8 funds opened new Milestone Pharmaceuticals positions in Q4 2023 and 7 closed out, a net change of +1 holder.
- The largest Milestone Pharmaceuticals buyer in Q4 2023 was Lion Point Capital, an estimated $3.26M added.
- The largest Milestone Pharmaceuticals seller in Q4 2023 was VR Adviser, an estimated $3.48M sold.
Based on aggregated 13F filings for Q4 2023.